一般社団法人JBCRG学会発表
2023年
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, Takashi Takeshita, Yuichiro Kikawa, Kokoro Kobayashi, Nobutaka Iwakuma, Takuho Okamura, Hiroshi Tada, Shinji Ozaki, Toshitaka Okuno, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, Hiroshi Ishiguro, Norikazu Masuda, Shigehira Saji
ESMO, 2023 Oct, Madrid Spain (ポスター)
ESMO
原発性HER2陽性乳癌に対するT-DM1術前薬物療法の可能性(JBCRG-20)
Norikazu Masuda, Mitsuya Ito, Yuko Tanabe, Kenichi Inoue, Kosuke Kawaguchi, Hiroyuki Yasojima, Toshimi Takano, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki Kataoka, Satoshi Morita, Masakazu Toi
第31回日本乳癌学会学術総会, 2023 Jul, Yokohama (ポスター
JBCS
ER陽性/HER陰性進行再発乳癌に対する酢酸メドロキシプロゲステロンの有効性に関する検討 Retrospective study using database for the effectiveness of medroxyprogesterone acetate in patients with ER-positive/HER2-negative postmenopausal advanced breast cancer: An additional analysis of the JBCRG-C06 Safari study
Mai Tomiguchi, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Koji Kaneko, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Masakazu Toi, Shinji Ohno
第31回日本乳癌学会学術総会, 2023 Jul, Yokohama (ポスター
JBCS
進行・再発乳癌におけるリアルワールドエビデンスの課題と展望
Yasuaki Sagara
第31回日本乳癌学会学術総会, 2023 Jun, Yokohama (シンポジウム）
JBCS
乳癌における包括的ゲノム診療の実際-JBCRG REIWA studyを通して-
Hiroko Masuda, Hiroshi Tada, Yayoi Adachi, Tsuguo Iwatani, Yasuaki Uemoto, Dai Kitagawa, Takahiro Kogawa, Yasuaki Sagara, Tadahiko Shien, Fumikata Hara, Hiroyuki Yasojima, Kenichi Yoshimura, Hiroji Iwata, Norikazu Masuda
第31回日本乳癌学会学術総会, 2023 Jun, Yokohama (シンポジウム）
JBCS
Pertuzumab retreatment in patients with HER2-positive locally advanced/ metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS).
Yutaka Yamamoto, Hiroji Iwata, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Naruto Taira, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno, Norikazu Masuda
ASCO, 2023 Jun, Chigago USA (Poster Discussion Session)
ASCO
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks)
Kenichi Inoue, Norikazu Masuda, Toshimi Takano, Mitsuya Ito, Yuko Tanabe, Kosuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R. Kataoka, Satoshi Morita, Masakazu Toi
ESMO Breast Cancer, 2023 May, Berlin Germany (Mini Oral)
ESMO